Co-Authors
This is a "connection" page, showing publications co-authored by MICHAEL JAMES OVERMAN and BRADLEY MCINTOSH BROOM.
Connection Strength
0.474
-
Phase I/II study of azacitidine and capecitabine/oxaliplatin (CAPOX) in refractory CIMP-high metastatic colorectal cancer: evaluation of circulating methylated vimentin. Oncotarget. 2016 Oct 11; 7(41):67495-67506.
Score: 0.148
-
Gene expression profiling of ampullary carcinomas classifies ampullary carcinomas into biliary-like and intestinal-like subtypes that are prognostic of outcome. PLoS One. 2013; 8(6):e65144.
Score: 0.118
-
Development and Validation of a Gene Signature Classifier for Consensus Molecular Subtyping of Colorectal Carcinoma in a CLIA-Certified Setting. Clin Cancer Res. 2021 01 01; 27(1):120-130.
Score: 0.049
-
Back to the Colorectal Cancer Consensus Molecular Subtype Future. Curr Gastroenterol Rep. 2019 Jan 30; 21(2):5.
Score: 0.044
-
Proteomic Features of Colorectal Cancer Identify Tumor Subtypes Independent of Oncogenic Mutations and Independently Predict Relapse-Free Survival. Ann Surg Oncol. 2017 Dec; 24(13):4051-4058.
Score: 0.040
-
Modeling of Patient-Derived Xenografts in Colorectal Cancer. Mol Cancer Ther. 2017 07; 16(7):1435-1442.
Score: 0.039
-
MET amplification in metastatic colorectal cancer: an acquired response to EGFR inhibition, not a de novo phenomenon. Oncotarget. 2016 08 23; 7(34):54627-54631.
Score: 0.037